Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen

Steven Rowe, Michael Gorin, Roberto A. Salas Fragomeni, Alexander Drzezga, Martin Gilbert Pomper

Research output: Contribution to journalArticle

Abstract

Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.

Original languageEnglish (US)
JournalPET Clinics
DOIs
StateAccepted/In press - 2016

Fingerprint

antigens
inhibitors
Prostatic Neoplasms
cancer
membranes
molecules
bones
Glycoproteins
tomography
Epithelial Cells
Tomography
Bone and Bones
human glutamate carboxypeptidase II
Neoplasms

Keywords

  • BAY 1075553
  • DCFBC
  • DCFPyL
  • Prostate cancer
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. / Rowe, Steven; Gorin, Michael; Salas Fragomeni, Roberto A.; Drzezga, Alexander; Pomper, Martin Gilbert.

In: PET Clinics, 2016.

Research output: Contribution to journalArticle

@article{5e3be594c8ed47218c090c959d112dcc,
title = "Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen",
abstract = "Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.",
keywords = "BAY 1075553, DCFBC, DCFPyL, Prostate cancer, Radiopharmaceutical",
author = "Steven Rowe and Michael Gorin and {Salas Fragomeni}, {Roberto A.} and Alexander Drzezga and Pomper, {Martin Gilbert}",
year = "2016",
doi = "10.1016/j.cpet.2016.12.006",
language = "English (US)",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen

AU - Rowe, Steven

AU - Gorin, Michael

AU - Salas Fragomeni, Roberto A.

AU - Drzezga, Alexander

AU - Pomper, Martin Gilbert

PY - 2016

Y1 - 2016

N2 - Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.

AB - Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.

KW - BAY 1075553

KW - DCFBC

KW - DCFPyL

KW - Prostate cancer

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=85009964428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009964428&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2016.12.006

DO - 10.1016/j.cpet.2016.12.006

M3 - Article

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

ER -